James River Group Holdings, Inc. (JRVR) is a specialty property-casualty insurance holding company that writes excess and surplus lines liability coverage and niche admitted programs through subsidiaries rated "A-" by A.M. Best. The stock fell 18.57% to $3.07 in early trading, compared with the prior session's close of $3.77, extending a year-to-date decline that had already reached roughly 40% before the open. The direction is clearly negative and the magnitude is far outside the shares' normal range. The immediate reason is unambiguous: third-quarter results published after Monday's close included a full write-off of goodwill, a large GAAP loss, fresh adverse reserve development and another quarter of double-digit premium contraction.
The headline number did the damage. James River recorded a non-cash impairment of its entire $181.8 million of goodwill tied to the Excess & Surplus Lines reporting unit, producing a net loss available to common shareholders of $189.4 million, or $4.08 per diluted share, versus a loss of $0.02 a year earlier. Consensus had pointed to positive earnings of roughly $0.19 per share, so the GAAP miss exceeded $4 per share.
Management attributed the write-off to the sustained decline in the share price and to excess and surplus market conditions affecting actual and projected results. The goodwill dates to the company's 2007 take-private transaction rather than any acquisition, and the charge does not affect statutory capital, adjusted operating results or debt covenant compliance — a distinction the market largely ignored. Shareholders' equity fell to $291.9 million from $538.2 million at year-end, and book value per share dropped to $6.31 from $11.71.
Beneath the accounting charge, operating trends were weak. The annual detailed reserve review produced $19.2 million of net adverse development in the E&S segment plus $1.4 million in Specialty Admitted, driven by a specific Product Liability portfolio now fully in runoff. That added 15 points to the E&S combined ratio, which reached 108.5% for the quarter; excluding the development it would have been 93.4%.
Adjusted net operating income swung to a $4.4 million loss from $17.4 million of income a year earlier. Gross written premium fell 22% to $186.1 million, net written premium slipped 14.4% and net earned premium declined 14% to $127.7 million, short of the $134.9 million analysts expected. The consolidated combined ratio of 115.6% means the company paid out more than it collected in underwriting. Offsets were limited but real: general and administrative expenses fell 9%, new and renewal submissions rose 8%, and net investment income edged up 1% to $22.2 million. The quarterly dividend was held at $0.01 per share.
The move was entirely idiosyncratic. The S&P 500 was down about 0.6% in the same window, yet the insurance sector benchmark was higher and large specialty peers — W.R. Berkley, RLI and Kinsale — each gained ground. Kemper was modestly lower but nowhere near James River's decline. Nothing in the macro backdrop or the underwriting cycle explains a gap of this size.
Volume confirmed conviction rather than noise. Roughly 95,000 shares traded in the first twenty minutes against an average full-session turnover near 277,000. The stock opened at $3.10, gapping below its prior 52-week low of $3.36, and traded between $3.03 and $3.21. That break of the prior floor leaves no nearby support on the chart, with the shares now quoted at roughly 0.39 times tangible common equity per share of $7.95.
A score of 0 would mean no meaningful news and a move that is ordinary for the stock; 100 would mean transformative news and an extreme, rare price move. JRVR earned 84 out of 100. The verified news was substantial — a full goodwill write-off, a GAAP loss that missed consensus by more than $4 per share, a second reserve charge tied to product liability, and a 22% decline in gross written premium — all material relative to a company valued near $140 million. The price response was equally rare: the decline was about eleven times the stock's 1.7% average absolute daily move over the past ninety sessions, and no session in the last sixty came close to matching it. Strong news and an unusually large reaction together justify the score.
Attention turns to the fourth quarter, typically reported in February, and to whether the Product Liability runoff book generates further development now that adverse development cover is largely exhausted. Investors will also watch whether the 8% submission growth converts into premium stabilization after four quarters of contraction, and whether expense reductions can offset a combined ratio above 115%. The dividend record date of December 15 provides a near-term marker of board confidence.
Consensus stands at Hold, and the earnings miss makes downward estimate revisions likely. Risks are concentrated: additional reserve strengthening, continued casualty price competition, and any pressure on the capital position as equity has nearly halved this year. Upside would require evidence that recent accident years are performing as management contends.
Tickeron's Trending AI Robots page curates the strongest performing automated strategies from a library of hundreds of bots spanning thousands of tickers. Each bot differs by strategy logic, trading timeframe, performance metrics and the symbols it trades, so results vary widely across market conditions. Only those currently outperforming are featured in this section, giving traders a focused shortlist rather than an exhaustive catalogue. Reviewing the featured bots is a practical way to see how systematic strategies are positioned right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
JRVR saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 09, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In 43 of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 88%.
The 10-day RSI Indicator for JRVR moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 16 similar instances where the indicator moved out of overbought territory. In 13 of the 16 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 54 cases where JRVR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JRVR as a result. In 78 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
JRVR moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JRVR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
JRVR broke above its upper Bollinger Band on October 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The 10-day moving average for JRVR crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Following a +3.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where JRVR advanced for three days, in 180 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 81 of 128 cases where JRVR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: JRVR's P/B Ratio (0.344) is slightly lower than the industry average of (0.987). P/E Ratio (7.939) is within average values for comparable stocks, (11.360). Projected Growth (PEG Ratio) (0.600) is also within normal values, averaging (0.944). Dividend Yield (0.010) settles around the average of (0.486) among similar stocks. JRVR's P/S Ratio (0.354) is slightly lower than the industry average of (2.529).
The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. JRVR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JRVR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 56, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a insurance company
Industry SpecialtyInsurance